FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890884853> ?p ?o ?g. }

• W2890884853 endingPage "6048" @default.
• W2890884853 startingPage "6039" @default.
• W2890884853 abstract "Phenformin and metformin inhibit growth and migration of LN229 glioma cells in vitro and in vivo Yanmin Wang,1 Yanli Meng,2 Shijun Zhang,1 Huancheng Wu,1 Dawei Yang,1 Chaohui Nie,1 Qunliang Hu1 1Department of Cerebral Surgery, Tianjin Beichen Hospital, Tianjin 300000, People’s Republic of China; 2Library, Tianjin Medical University, Tianjin 300000, People’s Republic of China Background: Malignant glioma is refractory to conventional treatment, highlighting a need to develop novel efficacious therapies. Biguanides, a class of oral antidiabetic drug, have been thought to inhibit proliferation and metastasis in a variety of cancers. Purpose: The objective of this study was to investigate the affections of biguanides, phenformin (Phen) and metformin (Met), on growth and migration of glioma cells LN229 in vitro and in vivo. Methods: Glioma cells LN229 were treated with Phen or Met, then cell proliferation and death were evaluated by MTT assay and PI stain, and cell cycle were evaluated using flow cytometric analysis, meantime wound healing assay and transwell migration assay were performed to detect cell migration ability. In addition, LN229 were injected in thigh of nude mice, and the mice were treated with Phen or Met to detect the effect of Phen and Met in vivo. Results: Phen and Met could significantly inhibit cell growth through inhibiting cell proliferation, promoting cell death and disturbing cell cycle, and these drugs also could inhibit cell colony formation in glioma cells LN229 in vitro. Meanwhile, both Phen and Met could significantly inhibit cell migration of LN229 in vitro, through effecting the expression of E-cadherin and Vimentin. In addition, both Phen and Met inhibited the growth and migration of LN229 in a tumor xenograft model. Furthermore, Phen and Met were associated with the increased level of ROS of cell mitochondrial, and ROS inhibitor NAC could significantly rescue the cell death induced by Phen and Met. Conclusion: Phen and Met displayed powerful antitumor effects of LN229, and our findings powerfully suggest the possibility of Phen and Met being used as an adjuvant agent in the treatment of glioma patients. Keywords: phenformin, metformin, glioma, LN229, proliferation, migration" @default.
• W2890884853 created "2018-09-27" @default.
• W2890884853 creator A5000120084 @default.
• W2890884853 creator A5013294486 @default.
• W2890884853 creator A5027419116 @default.
• W2890884853 creator A5040863807 @default.
• W2890884853 creator A5041972268 @default.
• W2890884853 creator A5042536232 @default.
• W2890884853 creator A5079747523 @default.
• W2890884853 date "2018-09-01" @default.
• W2890884853 modified "2023-09-26" @default.
• W2890884853 title "Phenformin and metformin inhibit growth and migration of LN229 glioma cells in vitro and in vivo" @default.
• W2890884853 cites W1636387298 @default.
• W2890884853 cites W1931273074 @default.
• W2890884853 cites W1997330696 @default.
• W2890884853 cites W2008256411 @default.
• W2890884853 cites W2013331748 @default.
• W2890884853 cites W2032389172 @default.
• W2890884853 cites W2046503553 @default.
• W2890884853 cites W2056753605 @default.
• W2890884853 cites W2061498899 @default.
• W2890884853 cites W2063739776 @default.
• W2890884853 cites W2090486591 @default.
• W2890884853 cites W2113038479 @default.
• W2890884853 cites W2166321298 @default.
• W2890884853 cites W2168974958 @default.
• W2890884853 cites W2198733978 @default.
• W2890884853 cites W2225179116 @default.
• W2890884853 cites W2283252377 @default.
• W2890884853 cites W2289712349 @default.
• W2890884853 cites W2319829114 @default.
• W2890884853 cites W2337980776 @default.
• W2890884853 cites W2344995542 @default.
• W2890884853 cites W2346529877 @default.
• W2890884853 cites W2416082321 @default.
• W2890884853 cites W2417470860 @default.
• W2890884853 cites W2484074474 @default.
• W2890884853 cites W2501225154 @default.
• W2890884853 cites W2516246423 @default.
• W2890884853 cites W2517130978 @default.
• W2890884853 cites W2534963778 @default.
• W2890884853 cites W2548044687 @default.
• W2890884853 cites W2558814374 @default.
• W2890884853 cites W2560855771 @default.
• W2890884853 cites W2598800586 @default.
• W2890884853 cites W2668372159 @default.
• W2890884853 cites W2750328639 @default.
• W2890884853 cites W2762942199 @default.
• W2890884853 cites W2533874479 @default.
• W2890884853 doi "https://doi.org/10.2147/ott.s168981" @default.
• W2890884853 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6157995" @default.
• W2890884853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30275708" @default.
• W2890884853 hasPublicationYear "2018" @default.
• W2890884853 type Work @default.
• W2890884853 sameAs 2890884853 @default.
• W2890884853 citedByCount "17" @default.
• W2890884853 countsByYear W28908848532020 @default.
• W2890884853 countsByYear W28908848532021 @default.
• W2890884853 countsByYear W28908848532022 @default.
• W2890884853 countsByYear W28908848532023 @default.
• W2890884853 crossrefType "journal-article" @default.
• W2890884853 hasAuthorship W2890884853A5000120084 @default.
• W2890884853 hasAuthorship W2890884853A5013294486 @default.
• W2890884853 hasAuthorship W2890884853A5027419116 @default.
• W2890884853 hasAuthorship W2890884853A5040863807 @default.
• W2890884853 hasAuthorship W2890884853A5041972268 @default.
• W2890884853 hasAuthorship W2890884853A5042536232 @default.
• W2890884853 hasAuthorship W2890884853A5079747523 @default.
• W2890884853 hasBestOaLocation W28908848531 @default.
• W2890884853 hasConcept C134018914 @default.
• W2890884853 hasConcept C137738243 @default.
• W2890884853 hasConcept C1491633281 @default.
• W2890884853 hasConcept C150903083 @default.
• W2890884853 hasConcept C185592680 @default.
• W2890884853 hasConcept C202751555 @default.
• W2890884853 hasConcept C207001950 @default.
• W2890884853 hasConcept C2778227246 @default.
• W2890884853 hasConcept C2778877718 @default.
• W2890884853 hasConcept C2780323712 @default.
• W2890884853 hasConcept C2780783641 @default.
• W2890884853 hasConcept C29537977 @default.
• W2890884853 hasConcept C502942594 @default.
• W2890884853 hasConcept C55493867 @default.
• W2890884853 hasConcept C555293320 @default.
• W2890884853 hasConcept C62112901 @default.
• W2890884853 hasConcept C71924100 @default.
• W2890884853 hasConcept C86803240 @default.
• W2890884853 hasConcept C98274493 @default.
• W2890884853 hasConceptScore W2890884853C134018914 @default.
• W2890884853 hasConceptScore W2890884853C137738243 @default.
• W2890884853 hasConceptScore W2890884853C1491633281 @default.
• W2890884853 hasConceptScore W2890884853C150903083 @default.
• W2890884853 hasConceptScore W2890884853C185592680 @default.
• W2890884853 hasConceptScore W2890884853C202751555 @default.
• W2890884853 hasConceptScore W2890884853C207001950 @default.
• W2890884853 hasConceptScore W2890884853C2778227246 @default.
• W2890884853 hasConceptScore W2890884853C2778877718 @default.
• W2890884853 hasConceptScore W2890884853C2780323712 @default.

• next